Financial Performance - Revenue for Q1 2022 was RMB 215,698,000, a decrease of 1.3% compared to RMB 219,289,000 in Q1 2021[8] - Gross profit for the period was RMB 97,543,000, down 17.5% from RMB 118,147,000 in the same period last year[8] - Profit before taxation decreased to RMB 14,842,000, a decline of 33.1% from RMB 22,312,000 in Q1 2021[11] - Net profit for the period was RMB 11,508,000, down 36.5% compared to RMB 18,073,000 in Q1 2021[11] - Earnings per share for the period was RMB 0.63, a decrease from RMB 0.93 in the same period last year[11] - The total comprehensive income attributable to owners of the company was RMB 10,541,000, down from RMB 15,648,000 in Q1 2021[11] - For the three months ended 31 March 2022, the Group reported an unaudited profit attributable to owners of approximately RMB 10,541,000, compared to approximately RMB 15,648,000 for the same period in 2021, indicating a decrease of about 32.5%[54] - The Group's profit after tax for the Reporting Period was approximately RMB 11,508,000, a decrease of approximately 36.32% from RMB 18,073,000 in the corresponding period last year[88] - Profit attributable to the owners of the Company was approximately RMB 10,541,000, representing a decrease of approximately 32.64% from RMB 15,648,000 in the corresponding period last year[88] Revenue Breakdown - Revenue from the manufacturing and selling of medicines was RMB 150,703,000, up 23.7% from RMB 121,789,000 in the previous year[31] - Revenue from the sales and distribution of healthcare products was RMB 64,995,000, down 33.3% from RMB 97,500,000 in the previous year[31] - Approximately RMB 150,703,000, which amounted to approximately 69.87% of the Group's total revenue, was derived from the manufacturing and selling of medicines segment, while approximately RMB 64,995,000, which amounted to approximately 30.13%, was from the sales and distribution of medicines and healthcare products segment[78] - Revenue from the manufacturing and selling of medicines segment increased by approximately 23.74% compared to the corresponding period of last year, while revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 33.34%[82] Expenses - Selling and distribution expenses were reduced to RMB 53,440,000, down 30.7% from RMB 77,118,000 in Q1 2021[8] - Administrative expenses increased to RMB 22,364,000, up 30.4% from RMB 17,175,000 in Q1 2021[8] - Staff costs increased to RMB 37,401,000, a rise of 42.6% from RMB 26,232,000 in the same period of 2021[39] - Depreciation of property, plant, and equipment was RMB 5,764,000, an increase of 40.1% from RMB 4,113,000 in the previous year[42] - Other operating expenses amounted to approximately RMB 8,261,000, representing an increase of approximately 36.30% from RMB 6,061,000 for the corresponding period of last year[86] - Administrative expenses during the Reporting Period were approximately RMB 22,364,000, an increase of approximately 30.21% from RMB 17,175,000 in the same period last year, primarily due to increased employee costs and expenses related to the acquisition of Haiwang Zhongxin[90] - Other operating expenses were approximately RMB 8,261,000, up approximately 36.30% from RMB 6,061,000 in the previous year, mainly due to increased R&D expenses following the acquisition of Haiwang Zhongxin[90] Financial Costs - Finance costs significantly decreased to RMB 1,650,000 from RMB 11,000 in Q1 2021[11] - Finance costs amounted to approximately RMB 1,650,000, representing an increase of approximately 14,900% from approximately RMB 11,000 for the corresponding period of last year[87] - Financial costs for the Reporting Period were approximately RMB 1,650,000, a significant increase of approximately 14,900% from RMB 11,000 in the same period last year, attributed to increased bank loan interest expenses from the acquisition[90] Corporate Governance - The Board does not recommend the payment of any dividend for the Reporting Period, consistent with the previous year[54] - The Company has complied with the requirements under the Corporate Governance Code during the Reporting Period[146] - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[140] - The Company is in the process of identifying a suitable candidate to fill the vacancy of the General Manager[145] - Neptunus Bio-engineering confirmed compliance with Non-Competition Undertakings during the Reporting Period[132] - The Audit Committee reviewed the unaudited consolidated results of the Group for the Reporting Period[139] - The Company has adopted a code of conduct regarding securities transactions by Directors, confirming no transactions were conducted during the Reporting Period[133] Research and Development - Research and development costs for the period were RMB 6,897,000, an increase from RMB 5,320,000 in the previous year[42] - The Group's research and development efforts focus on internal demands and collaborations with external institutions, resulting in several new drugs and exclusive products with self-owned intellectual property rights[61] Market Strategy - Neptunus Zhongxin has implemented diversified marketing strategies and expanded its distributor coverage to navigate increasing regulatory and competitive pressures in the pharmaceutical industry[65] - The Group's pharmaceutical subsidiaries are actively strengthening management and collaborating directly with raw material suppliers to ensure production needs are met amid rising costs and regulatory pressures[66] Shareholding Structure - The controlling shareholder, Neptunus Bio-engineering, held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Neptunus Oriental[109] - Substantial shareholder Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing approximately 94.33% of all domestic shares and 70.38% of the Company's issued share capital[120] - Neptunus Group is deemed to be interested in 1,233,464,500 domestic shares, which is approximately 98.52% of all domestic shares and 73.51% of the Company's issued share capital[120] Compliance and Regulations - The Company and its subsidiaries have not adopted any share option scheme or granted any options, convertible securities, or warrants as of March 31, 2022[112] - The Company and its subsidiaries did not purchase, redeem, or sell any of the Company's listed securities during the Reporting Period[125] - As of March 31, 2022, the Directors and supervisors are not aware of any other persons holding interests or short positions in the shares of the Company[124]
海王英特龙(08329) - 2022 Q1 - 季度财报